|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||32.70 - 32.99|
|52 Week Range||26.30 - 34.98|
|Beta (3Y Monthly)||0.46|
|PE Ratio (TTM)||21.39|
|Forward Dividend & Yield||1.07 (3.25%)|
|1y Target Est||37.90|
Venture capitalist Jim Breyer, the CEO of Breyer Capital, speaks with Yahoo Finance's Julia La Roche about investing in artificial intelligence.
Nassim Nicholas Taleb, the best-selling author of "The Black Swan," speaks to Yahoo Finance's Julia La Roche at the 2019 SALT Conference in Las Vegas.
Award-winning entertainment reporter Maria Menounos talks to Yahoo Finance's Julia La Roche about the future of entertainment television.
Walmart is out with its quarterly earnings, beating expectations. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Julia La Roche discuss.
Walmart announces next-day shipping for nearly 200,000 products. It's rolling out in Phoenix, Las Vegas and Southern California first. Yahoo Finance's Julia La Roche and Seana Smith discuss.
China's leading streaming music provider beat Wall St's estimate on earnings, but revenue growth of 39% fell short of expectations. Plus an executive shakeup is worrying investors. Meanwhile, investors watching closely at Alibaba's earnings out tomorrow. Yahoo Finance's Julia La Roche joins Seana Smith.
Walmart is ramping up its competition against Amazon, and announced that it’s debuting a one-day delivery service in select markets. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, Julia La Roche break down the details.
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta offers ...
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase ...
– Phase I/II study of entrectinib, an investigational medicine, showed responses in all pediatric tumor types harboring neurotrophic tyrosine receptor kinase , ROS1 or anapla
OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Venclexta® (venetoclax) in combination with Gazyva® (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). “Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without progression of their disease, compared to a standard of care,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development.
AstraZeneca (ZN) needs a blockbuster to justify its nearly $7 billion investment for a share of Japan-based Daiichi Sankyo's (TSE:4568) drug to treat a type of breast cancer. Warning! GuruFocus has detected 5 Warning Signs with AZN. The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with another drug combination.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...
Swiss drugmaker Roche is pushing back its $4.3 billion (3.3 billion pounds) takeover offer for gene therapy specialist Spark Therapeutics for a third time in recent months, this time until June 14, as a U.S. regulatory review of the deal drags on. Roche and Spark are now due to refile their premerger notification on May 23, "in order to provide the government with additional time," the companies said in a joint statement on Tuesday. Roche has said the Federal Trade Commission (FTC) needed even more time to complete its review.
OTCQX: RHHBY) today announced the CE-IVD launch of the cobas® MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA. This assay is part of the mycobacteria test menu that includes the cobas® MTB and cobas® MAI tests for use on the cobas® 6800/8800 Systems.
OTCQX: RHHBY) and Spark Therapeutics, Inc. (ONCE) ("Spark") today announced that Roche and Spark intend to refile on or about 23 May 2019 their respective Premerger Notification and Report Forms under the Hart-Scott-Rodino Act (the "HSR Act") in connection with Roche`s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated 7 March 2019 (as it may be amended and supplemented from time to time, the "Offer"). Following the refiling by Roche, the waiting period applicable to the pending acquisition will expire at 11:59 p.m., New York City time, on or about 7 June 2019, but this period may be shortened if the government grants "early termination" of the waiting period, or it may change if Roche voluntarily withdraws and Roche refiles its Premerger Notification and Report Forms in order to restart the 15-day waiting period or if the reviewing agency issues a formal request for additional information and documentary material.